Orthofix Medical AI Stock Analysis
Orthofix Medical (OM2) AI Stock Analysis
Orthofix Medical
(Frankfurt:OM2)
No summary available
Orthofix Medical (OM2) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 269.42M
- Dividend Yield
- ―
- Average Volume (3M)
- 25
- Price to Earnings (P/E)
- -5.9
- Beta (1Y)
- 0.35
- Revenue Growth
- -2.99%
- EPS Growth
- 66.06%
- Country
- Germany
- Employees
- 1,605
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Orthofix Medical Business Overview & Revenue Model
Company Description
Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Ge...
Orthofix Medical Earnings Call Summary
The call presented a mixed outlook. Limb Reconstruction, Therapeutic Solutions, Biologics stabilization, technology launches and improved adjusted EBITDA were positive, but these were offset by below-expectation results, U.S. Spine weakness, supplier and instrument constraints, reduced 2026 guidance, unfavorable mix, cash timing pressure and a stated 2027 MDR revenue headwind.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Orthofix now expects full year 2026 pro forma net sales in the range of $825 million to $830 million and full year 2026 non-GAAP adjusted EBITDA of $86 million to $88 million, with the outlook provided on a non-GAAP pro forma basis, reflecting current foreign currency exchange rates and excluding the discontinued M6 product lines. For the fourth quarter, the company expects sequential growth from normal seasonality and inventory purchases under the European distributor arrangement, with most of the approximately $15 million 2026 net sales benefit expected in the fourth quarter. The European MDR strategy for Spine is expected to create an approximately $22 million net sales headwind in 2027, while MDR requirements are completed. The company is not providing full guidance on 2027, but expects Therapeutic Solutions and limb recon to show above-market growth, core revenue to be in the positive territory backing out the MDR, and Q3, Q4 performance to continue into 2027; core distributors’ growth slowed to the mid-single digits.
Orthofix Medical Risk Analysis
Orthofix Medical disclosed 54 risk factors in its most recent earnings report. Orthofix Medical reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
1 New RiskOrthofix Medical Peers Comparison
Overall Rating
GMED73Outperform
SIBN70Outperform
BVS66Neutral
ENOV58Neutral
ATEC50Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 73Outperform | $9.27B | 17.04 | 11.82% | ― | 13.35% | 32.22% | |
| 70Outperform | $1.04B | -75.98 | -7.57% | ― | 13.99% | 39.54% | |
| 66Neutral | $894.85M | 12.55 | 27.23% | ― | 3.87% | 623.68% | |
| 58Neutral | $1.56B | -2.92 | -35.53% | ― | 3.28% | 62.02% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | $1.10B | -12.61 | -547.17% | ― | 15.34% | 46.31% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:OM2 | Orthofix Medical Inc. | 5.90 | -6.40 | -52.03% | |
| ATEC | Alphatec | 7.06 | -12.55 | -64.00% | |
| ENOV | Enovis Corporation | 27.10 | 0.27 | 1.01% | |
| GMED | Globus Medical | 70.53 | -11.75 | -14.28% | |
| SIBN | Si-Bone | 23.54 | 4.86 | 26.02% | |
| BVS | Bioventus, Inc. | 10.62 | 4.09 | 62.63% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
